Generics

Everolimus tablets had a market value of roughly $150 million in the 12 months ended January 2020, according to IQVIA.

Biosimilars could reduce patient's out-of-pocket costs by 17%, according to a new study by the Center for Medical Economics at the Pacific Research Institute.

Advair Diskus had a market value of $113.9 million in Canada for the 12 months ended Dec. 31, 2019, according to IQVIA.

Zydus Cadila has received the FDA's nod for generic Truvada 200 mg/300 mg, and tentative approval for additional dosage strengths.

Naproxen and esomeprazole magnesium delayed-release tablets had a market value of roughly $400 million, according to IQVIA January 2020 data.

The combined Thiotepa brand and generic had a market value of more than $36.5 million for the previous 12 months.

As part of a resolution with the U.S. Department of Justice Antitrust Division, Sandoz has agreed to pay $195 million.

In the wake of the coronavirus spreading, the Association for Accessible Medicines said it will work to help ensure that patients in the United States get access to generic and biosimilar medicines.